Primary Epstein–Barr virus infection diffusing F18-fluorodeoxyglucose-positron emission tomography/computed tomography response monitoring of Hodgkin’s disease: a case report by Hans Balink & Mels Hoogendoorn
JOURNAL OF MEDICAL
CASE REPORTS
Balink and Hoogendoorn Journal of Medical Case Reports 2014, 8:212
http://www.jmedicalcasereports.com/content/8/1/212CASE REPORT Open AccessPrimary Epstein–Barr virus infection diffusing
F18-fluorodeoxyglucose-positron emission
tomography/computed tomography response
monitoring of Hodgkin’s disease: a case report
Hans Balink1* and Mels Hoogendoorn2Abstract
Introduction: Hodgkin’s disease is highly curable by radiotherapy and/or chemotherapy, but refractory disease or
early relapses are rarely cured by conventional salvage therapy.
Case presentation: We report a case of a 20-year-old Caucasian man, with a biopsy-proven intrapulmonary relapse
of Hodgkin’s disease, for whom salvage chemotherapy was administered. During salvage chemotherapy intense
increased F18-fluorodeoxyglucose uptake was noticed in multiple lymph nodes and diffuse increased splenic uptake,
suggesting chemotherapy-refractory disease. However, additional information obtained from the patient revealed he
recently had met his first girlfriend. An asymptomatic primary Epstein–Barr virus infection was considered proven.
Conclusions: Interim F18-fluorodeoxyglucose-positron emission tomography/computed tomography is a strong
prognostic factor for advanced Hodgkin’s and may better identify those patients needing intensified chemotherapy.
Related to the nonspecificity of F18-fluorodeoxyglucose, clinical awareness of the potential interference of intercurrent
asymptomatic viral infections with treatment and remission status monitoring continues to be important in the
interpretation of equivocal medical imaging results.
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Hodgkin’s disease (HD) is highly curable by radiother-
apy and/or chemotherapy, but refractory disease or
early relapses are rarely cured by conventional salvage
therapy [1].
Additional high-dose chemotherapy (HDCT), such as
carmustine, etoposide, cytarabine and melphalan (BEAM)
in combination with autologous stem-cell transplantation
(ASCT), is used to salvage and cure these patients. Since
only chemosensitive patients with relapsed HD benefit
from ablative therapy and ASCT, adequate response to sal-
vage chemotherapy, assessed by serial positron emission
tomography/computed tomography (PET/CT) is pivotal to* Correspondence: hans.balink@znb.nl
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article, unless otherwise stated.progress to HDCTand ASCT. We report a case of a young
man with early intrapulmonary relapse of HD in whom
during salvage chemotherapy on interim PET/CT general-
ized PET-positive lymphadenopathy was observed, caused
by a primary Epstein–Barr virus (EBV) infection and not
by progressive disease.Case presentation
A 20-year-old Caucasian man was diagnosed with nodular
sclerosing HD stage III-SA with an International Prognos-
tic Score (IPS) of 2 with cervical, supraclavicular, axillary
retroperitoneal lymph node localizations, with a bulky
mediastinal mass and a splenic nodule on PET/CT with
F18-fluorodeoxyglucose (FDG). A response evaluation
8 months later after six cycles of Adriamycin® (doxo-
rubicin), bleomycin, vinblastine, and dacarbazine with
F18-FDG-PET/CT showed a major, both morphologicMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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bolic activity in his left hilar region for which additional
infranodal radiotherapy (in total 15×2Gy) on the medias-
tinal mass was given. Four months later, after radiotherapy
the response evaluation by PET/CT revealed three meta-
bolic active extranodal lesions in his left lung. Relapse of
HD was histologically proven using CT-guided biopsy
(Figure 1).
Salvage chemotherapy consisted of two cycles of cisplati-
num, cytarabine, and dexamethasone (DHAP) and one
cycle of etoposide, ifosfamide, and methotrexate (VIM),
followed by ASCT with BEAM conditioning was proposed.
Response evaluation using interim F18-FDG-PET/CT,
after one cycle of DHAP and VIM chemotherapy showed
a partial metabolic response in his lung nodes, his max-
imum standardized uptake value (SUVmax) decreased
from 12 and 15 in left upper and lower lobe respectively,
to SUVmax 6 and 8.
New symmetrical intense FDG uptake in his adenoids
(SUVmax 24), and in multiple bilateral cervical (SUV-
max 10), axillary lymph nodes and in a lymph node
within the high-right para-aorta (SUVmax 6.5) and a
lower-right mesenteric lymph node, with furthermore
diffuse increased splenic F18-FDG uptake (SUVmax 6)
suggested rapidly progressive disease (Figure 2). How-
ever, the coincidence of both an extensive nodular re-
lapse with a partial response of the extranodal lung
lesions was regarded unlikely. Additional information
obtained from the patient revealed he had recently metFigure 1 Interim F18-fluorodeoxyglucose-positron emission
tomography/computed tomography revealed biopsy/histology-
proven intrapulmonary relapse of Hodgkin’s disease after six
cycles of Adriamycin® (doxorubicin), bleomycin, vinblastine,
dacarbazine and infranodal radiotherapy of a mediastinal
mass. The left image is the total body maximum intensity
projection image. The coinciding transverse positron emission
tomography and computed tomography slices show the caudal
lesion of a total of three lesions in the left lung (black arrows).his first girlfriend. Additional virus serology tests showed
EBV-specific immunoglobulin M antibodies and EBV
deoxyribonucleic acid (DNA) copies in peripheral blood.
We hypothesized that the asymptomatic primary EBV
infection was responsible for the extensive PET-positive
lymphadenopathy with a concurrent partial response of
HD after DHAP-VIM chemotherapy. After disappearance
of EBV DNA copies the second DHAP chemotherapy
cycle was given without flare-up of the infection.
An interim PET/CT, 2 months after completion of the
last DHAP chemotherapy and with absence of EBV
DNA in peripheral blood showed metabolic activity in
only one of the three lung lesions and only marginal in-
creased activity in a (probably reactive) small mediastinal
pre-aortal lymph node (Figure 3). After extensive discus-
sion, he progressed to ASCT and subsequent BEAM
conditioning chemotherapy. In the event of extrapul-
monary disease progression, he will be considered for
treatment with brentuximab vedotin (an antibody-drug
conjugate directed to the protein CD30).
Discussion
EBV is a widely distributed gammaherpesvirus; approxi-
mately 90% of adults throughout the world are EBV-
positive. Exposure to EBV predominantly occurs in early
adulthood. EBV may cause a number of clinical syn-
dromes, including acute mononucleosis and has been as-
sociated with a variety of malignancies, including B-cell
and T-cell lymphoma [2]. Acute primary infection with
EBV is mostly characterized by transient fever, lymph-
adenopathy and may cause a transient hepatosplenome-
galy. The severity and presentation may range from an
asymptomatic infection to a serious life-threatening ver-
sion of mononucleosis with associated liver damage or
even rupture of the spleen [3]. Our patient elegantly il-
lustrates that a subclinical primary EBV infection may
intervene with both the treatment of HD and remission
status judgment. Since PET/CT is rarely used as a diag-
nostic tool to detect a primary EBV infection in daily
clinical practice, only a few case reports have been pub-
lished. These cases demonstrated that F18-FDG uptake
can be intense in lymph nodes and spleen and may
mimic lymphoma [4-6]. The choice to opt for interim
F18-FDG PET/CT scans was not only based on the com-
bination of the young age of our patient and the prog-
nostic implications of his relapse. Interim PET is the
strongest prognostic factor that is reported for advanced
HD, and overshadows the impact of the IPS [7,8]. This
case report also supports that better risk stratification,
based on early interim (PET) evaluation, may better identify
those patients needing intensified chemotherapy. Further-
more, in larger studies the intensification of chemotherapy
and the optimal use of PET at the end of chemotherapy
have already minimized the use of radiotherapy in
Figure 2 The second interim F18-fluorodeoxyglucose-positron emission tomography/computed tomography after cycles of
cisplatinum, cytarabine, and dexamethasone, and etoposide, ifosfamide and methotrexate, showing decreased metabolic activity in
the three lesions in the left lung indicating partial response. However, new pathological increased fluorodeoxyglucose uptake is seen in
multiple bilateral cervical plus axillary lymph nodes and furthermore increased metabolic activity in the spleen and in a lymph node within the
high-right para-aortal and in a lower-right mesenteric lymph node (black arrows). Virus serology was positive for Epstein–Barr virus.
Figure 3 F18-fluorodeoxyglucose-positron emission tomography/computed tomography after completion of chemotherapy with
cisplatinum, cytarabine, and dexamethasone-etoposide, ifosfamide, and methotrexate cisplatinum, cytarabine, and dexamethasone
and absence of Epstein–Barr virus deoxyribonucleic acid in peripheral blood. Only the most apical of the three lesions in the left lung is
still metabolically active. Minor activity is seen in a small pre-aortal lymph node (thick arrows).
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complications [9].
Conclusions
We describe a case with pulmonary relapse of HD, in
whom an asymptomatic primary EBV infection was di-
agnosed during salvage chemotherapy on suggestion of
the interim PET/CT. Clinical awareness of intercurrent
asymptomatic viral infections, potentially interfering with
treatment and remission status monitoring remain im-
portant in the interpretation of equivocal medical imaging
results.
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